| 1 |
34232979 |
10.1182/blood.2020010039 |
2022 |
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. |
CD79B |
| 2 |
34448823 |
10.1182/bloodadvances.2021004212 |
2022 |
The molecular hallmarks of primary and secondary vitreoretinal lymphoma. |
CD79B |
| 3 |
34638136 |
10.1182/bloodadvances.2020003698 |
2022 |
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. |
CD79B |
| 4 |
34654055 |
10.1182/bloodadvances.2021006034 |
2022 |
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. |
CD79B |
| 5 |
34904799 |
10.1056/NEJMoa2115304 |
2022 |
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. |
CD79B |
| 6 |
34980599 |
10.1158/1078-0432.CCR-21-3261 |
2022 |
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. |
CD79B |
| 7 |
35028710 |
10.1007/s00428-021-03265-5 |
2022 |
Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. |
CD79B |
| 8 |
35126963 |
10.1177/20406207211072839 |
2022 |
MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. |
CD79B |
| 9 |
35169086 |
10.11477/mf.1436204531 |
2022 |
[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. |
CD79B |
| 10 |
35210172 |
10.1016/j.preteyeres.2022.101053 |
2022 |
Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches. |
CD79B |
| 11 |
35223507 |
10.3389/fonc.2022.824632 |
2022 |
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. |
CD79B |
| 12 |
35236331 |
10.1186/s12885-022-09237-5 |
2022 |
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. |
CD79B |
| 13 |
35240681 |
10.1182/bloodadvances.2021006801 |
2022 |
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. |
CD79B |
| 14 |
35255429 |
10.1016/j.anndiagpath.2021.151886 |
2022 |
De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. |
CD79B |
| 15 |
35326604 |
10.3390/cancers14061453 |
2022 |
DLBCL 1L-What to Expect beyond R-CHOP? |
CD79B |
| 16 |
35401516 |
10.3389/fimmu.2022.842439 |
2022 |
Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. |
CD79B |
| 17 |
35538064 |
10.1038/s41467-022-30050-y |
2022 |
The genomic and transcriptional landscape of primary central nervous system lymphoma. |
CD79B |
| 18 |
35554927 |
10.1002/eji.202149746 |
2022 |
Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas. |
CD79B |
| 19 |
35646048 |
10.3389/fgene.2022.878618 |
2022 |
Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
CD79B |
| 20 |
35663281 |
10.1016/j.lrr.2022.100325 |
2022 |
Immunotherapy in indolent Non-Hodgkin's Lymphoma. |
CD79B |
| 21 |
35726803 |
10.1080/14737140.2022.2093191 |
2022 |
Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma. |
CD79B |
| 22 |
35759728 |
10.1182/blood.2022015926 |
2022 |
Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. |
CD79B |
| 23 |
35764309 |
10.1111/bjh.18341 |
2022 |
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. |
CD79B |
| 24 |
35807041 |
10.3390/jcm11133748 |
2022 |
BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study. |
CD79B |
| 25 |
35908982 |
10.1016/j.blre.2022.100992 |
2022 |
Follicular lymphoma: The long and winding road leading to your cure? |
CD79B |
| 26 |
35917107 |
10.1111/bjh.18384 |
2022 |
United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma. |
CD79B |
| 27 |
35928872 |
10.3389/fonc.2022.932674 |
2022 |
Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma. |
CD79B |
| 28 |
35933930 |
10.1016/j.ctrv.2022.102443 |
2022 |
Treatment strategies for patients with diffuse large B-cell lymphoma. |
CD79B |
| 29 |
35937947 |
10.1155/2022/6441139 |
2022 |
Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis. |
CD79B |
| 30 |
35963895 |
10.1007/s00262-022-03267-5 |
2022 |
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies. |
CD79B |
| 31 |
36006771 |
10.1097/PAS.0000000000001957 |
2022 |
Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study. |
CD79B |
| 32 |
36051079 |
10.1002/jha2.428 |
2022 |
Targetable alterations in primary extranodal diffuse large B-cell lymphoma. |
CD79B |
| 33 |
36059608 |
10.3389/fonc.2022.955080 |
2022 |
Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis. |
CD79B |
| 34 |
36081566 |
10.3389/fonc.2022.941347 |
2022 |
Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. |
CD79B |
| 35 |
32273478 |
10.3324/haematol.2020.251579 |
2021 |
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. |
CD79B |
| 36 |
32500753 |
10.1080/14712598.2020.1777979 |
2021 |
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. |
CD79B |
| 37 |
32583848 |
10.1093/neuonc/noaa145 |
2021 |
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. |
CD79B |
| 38 |
32954807 |
10.2217/fon-2020-0675 |
2021 |
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. |
CD79B |
| 39 |
33202420 |
10.1182/blood.2020008520 |
2021 |
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. |
CD79B |
| 40 |
33232972 |
10.1182/blood.2020005244 |
2021 |
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. |
CD79B |
| 41 |
33273056 |
10.1158/1535-7163.MCT-20-0046 |
2021 |
An Anti-CD22-<i>seco</i>-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. |
CD79B |
| 42 |
33314668 |
10.1111/ijlh.13420 |
2021 |
Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features. |
CD79B |
| 43 |
33452395 |
10.1038/s41598-021-81000-5 |
2021 |
EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex. |
CD79B |
| 44 |
33479306 |
10.1038/s41598-020-80376-0 |
2021 |
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. |
CD79B |
| 45 |
33512416 |
10.1182/blood.2020007245 |
2021 |
Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. |
CD79B |
| 46 |
33561953 |
10.3390/cancers13040650 |
2021 |
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. |
CD79B |
| 47 |
33562532 |
10.3390/cancers13040630 |
2021 |
Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis. |
CD79B |
| 48 |
33581493 |
10.1016/j.ctarc.2021.100310 |
2021 |
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. |
CD79B |
| 49 |
33583077 |
10.1002/hon.2842 |
2021 |
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. |
CD79B |
| 50 |
33639170 |
10.1016/j.jbc.2021.100465 |
2021 |
TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells. |
CD79B |
| 51 |
33747936 |
10.3389/fonc.2021.622648 |
2021 |
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. |
CD79B |
| 52 |
33777778 |
10.3389/fonc.2021.628807 |
2021 |
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. |
CD79B |
| 53 |
33935029 |
10.5045/br.2021.2020320 |
2021 |
Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas. |
CD79B |
| 54 |
33942442 |
10.1111/cas.14937 |
2021 |
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. |
CD79B |
| 55 |
34204385 |
10.3390/cancers13123032 |
2021 |
Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing. |
CD79B |
| 56 |
34236648 |
10.1007/978-1-0716-1669-7_20 |
2021 |
Generation and Surgical Analysis of Genetic Mouse Models to Study NF-κB-Driven Pathogenesis of Diffuse Large B Cell Lymphoma. |
CD79B |
| 57 |
34254378 |
10.1111/neup.12739 |
2021 |
Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases. |
CD79B |
| 58 |
34256851 |
10.1186/s40364-021-00309-5 |
2021 |
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. |
CD79B |
| 59 |
34327781 |
10.1111/cas.15091 |
2021 |
Current progress and future perspectives of research on intravascular large B-cell lymphoma. |
CD79B |
| 60 |
34595463 |
10.2991/chi.k.210305.001 |
2021 |
Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma. |
CD79B |
| 61 |
34604075 |
10.3389/fonc.2021.737645 |
2021 |
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. |
CD79B |
| 62 |
34657049 |
NA |
2021 |
[Circulating Tumor DNA Analysis in Lymphomas]. |
CD79B |
| 63 |
34706861 |
10.1136/bjophthalmol-2021-319580 |
2021 |
Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma. |
CD79B |
| 64 |
34739844 |
10.1016/j.ccell.2021.10.006 |
2021 |
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. |
CD79B |
| 65 |
34745101 |
10.3389/fimmu.2021.732006 |
2021 |
International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma. |
CD79B |
| 66 |
34768899 |
10.3390/ijms222111470 |
2021 |
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. |
CD79B |
| 67 |
34925435 |
10.3389/fgene.2021.677650 |
2021 |
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. |
CD79B |
| 68 |
34944954 |
10.3390/cancers13246334 |
2021 |
Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System. |
CD79B |
| 69 |
35116576 |
10.21037/tcr-20-2525 |
2021 |
Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database. |
CD79B |
| 70 |
29629945 |
10.1097/PAI.0000000000000655 |
2020 |
Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
CD79B |
| 71 |
31123031 |
10.3324/haematol.2018.214122 |
2020 |
<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. |
CD79B |
| 72 |
31609782 |
10.1097/PAS.0000000000001386 |
2020 |
Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma. |
CD79B |
| 73 |
31624374 |
10.1038/s41375-019-0607-5 |
2020 |
T cells redirected against Igβ for the immunotherapy of B cell lymphoma. |
CD79B |
| 74 |
31693429 |
10.1200/JCO.19.00172 |
2020 |
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. |
CD79B |
| 75 |
31738823 |
10.1182/blood.2019002699 |
2020 |
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. |
CD79B |
| 76 |
31739126 |
10.1016/j.cancergen.2019.11.002 |
2020 |
Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. |
CD79B |
| 77 |
31863183 |
10.1007/s00428-019-02698-3 |
2020 |
Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. |
CD79B |
| 78 |
31894255 |
10.3892/ijmm.2019.4418 |
2020 |
Precision medicine for human cancers with Notch signaling dysregulation (Review). |
CD79B |
| 79 |
32056332 |
10.1111/cas.14347 |
2020 |
Gene expression profiling of primary vitreoretinal lymphoma. |
CD79B |
| 80 |
32060403 |
10.1038/s41375-020-0743-y |
2020 |
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. |
CD79B |
| 81 |
32083995 |
10.1200/JCO.19.02314 |
2020 |
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. |
CD79B |
| 82 |
32127472 |
10.1073/pnas.1921187117 |
2020 |
Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14. |
CD79B |
| 83 |
32172360 |
10.1007/s11899-020-00572-7 |
2020 |
Polatuzumab Vedotin: a New Target for B Cell Malignancies. |
CD79B |
| 84 |
32201861 |
10.1093/noajnl/vdaa018 |
2020 |
Primary CNS lymphoma commonly expresses immune response biomarkers. |
CD79B |
| 85 |
32239385 |
10.1007/s11523-020-00710-4 |
2020 |
Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. |
CD79B |
| 86 |
32309823 |
10.1358/dot.2020.56.4.3127026 |
2020 |
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. |
CD79B |
| 87 |
32322395 |
10.1186/s40364-020-00189-1 |
2020 |
TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients. |
CD79B |
| 88 |
32399964 |
10.1002/ijc.33049 |
2020 |
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. |
CD79B |
| 89 |
32420699 |
10.1002/cam4.3136 |
2020 |
Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. |
CD79B |
| 90 |
32495161 |
10.1007/s11523-020-00729-7 |
2020 |
Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. |
CD79B |
| 91 |
32497402 |
10.1002/cyto.b.21887 |
2020 |
Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma. |
CD79B |
| 92 |
32510610 |
10.1002/hon.2761 |
2020 |
On point in primary CNS lymphoma. |
CD79B |
| 93 |
32606733 |
10.2147/OTT.S219449 |
2020 |
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data. |
CD79B |
| 94 |
32641598 |
10.3960/jslrt.20010 |
2020 |
Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma. |
CD79B |
| 95 |
32695560 |
10.2176/nmccrj.cr.2019-0241 |
2020 |
Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature. |
CD79B |
| 96 |
32700586 |
10.1080/17474086.2020.1795828 |
2020 |
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma. |
CD79B |
| 97 |
32700972 |
10.1080/13543784.2020.1800638 |
2020 |
Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. |
CD79B |
| 98 |
32736575 |
10.1186/s12885-020-07198-1 |
2020 |
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma. |
CD79B |
| 99 |
32745612 |
10.1016/j.jmoldx.2020.07.002 |
2020 |
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. |
CD79B |
| 100 |
32770353 |
10.1007/s00280-020-04119-8 |
2020 |
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. |
CD79B |
Datasets
Models
